1038 related articles for article (PubMed ID: 14529766)
1. Improvement in relapse-free survival throughout the PSA era in patients with localized prostate cancer treated with definitive radiotherapy: year of treatment an independent predictor of outcome.
Kupelian PA; Buchsbaum JC; Elshaikh MA; Reddy CA; Klein EA
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):629-34. PubMed ID: 14529766
[TBL] [Abstract][Full Text] [Related]
2. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452
[TBL] [Abstract][Full Text] [Related]
3. Impact of biochemical failure on overall survival after radiation therapy for localized prostate cancer in the PSA era.
Kupelian PA; Buchsbaum JC; Patel C; Elshaikh M; Reddy CA; Zippe C; Klein EA
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):704-11. PubMed ID: 11849793
[TBL] [Abstract][Full Text] [Related]
4. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.
Kupelian P; Kuban D; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A
Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):415-9. PubMed ID: 15667961
[TBL] [Abstract][Full Text] [Related]
5. Higher than standard radiation doses (> or =72 Gy) with or without androgen deprivation in the treatment of localized prostate cancer.
Kupelian PA; Mohan DS; Lyons J; Klein EA; Reddy CA
Int J Radiat Oncol Biol Phys; 2000 Feb; 46(3):567-74. PubMed ID: 10701735
[TBL] [Abstract][Full Text] [Related]
6. Radiation dose response in patients with favorable localized prostate cancer (Stage T1-T2, biopsy Gleason < or = 6, and pretreatment prostate-specific antigen < or = 10).
Kupelian PA; Buchsbaum JC; Reddy CA; Klein EA
Int J Radiat Oncol Biol Phys; 2001 Jul; 50(3):621-5. PubMed ID: 11395228
[TBL] [Abstract][Full Text] [Related]
7. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
Kupelian PA; Katcher J; Levin HS; Klein EA
Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1043-52. PubMed ID: 9169811
[TBL] [Abstract][Full Text] [Related]
8. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
[TBL] [Abstract][Full Text] [Related]
9. Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality.
Kollmeier MA; Stock RG; Stone N
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):645-53. PubMed ID: 14529768
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: a large single-institution experience with radical prostatectomy and external-beam radiotherapy.
Kupelian PA; Elshaikh M; Reddy CA; Zippe C; Klein EA
J Clin Oncol; 2002 Aug; 20(16):3376-85. PubMed ID: 12177097
[TBL] [Abstract][Full Text] [Related]
11. Stage T1-2 prostate cancer with pretreatment prostate-specific antigen level < or = 10 ng/ml: radiation therapy or surgery?
Keyser D; Kupelian PA; Zippe CD; Levin HS; Klein EA
Int J Radiat Oncol Biol Phys; 1997 Jul; 38(4):723-9. PubMed ID: 9240638
[TBL] [Abstract][Full Text] [Related]
12. Factors affecting recurrence rates after prostatectomy or radiotherapy in localized prostate carcinoma patients with biopsy Gleason score 8 or above.
Kupelian PA; Buchsbaum JC; Elshaikh M; Reddy CA; Zippe C; Klein EA
Cancer; 2002 Dec; 95(11):2302-7. PubMed ID: 12436435
[TBL] [Abstract][Full Text] [Related]
13. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.
Vargas C; Kestin LL; Weed DW; Krauss D; Vicini FA; Martinez AA
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):714-24. PubMed ID: 15708249
[TBL] [Abstract][Full Text] [Related]
14. External beam radiotherapy dose response characteristics of 1127 men with prostate cancer treated in the PSA era.
Pollack A; Smith LG; von Eschenbach AC
Int J Radiat Oncol Biol Phys; 2000 Sep; 48(2):507-12. PubMed ID: 10974469
[TBL] [Abstract][Full Text] [Related]
15. Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer.
Kupelian PA; Potters L; Khuntia D; Ciezki JP; Reddy CA; Reuther AM; Carlson TP; Klein EA
Int J Radiat Oncol Biol Phys; 2004 Jan; 58(1):25-33. PubMed ID: 14697417
[TBL] [Abstract][Full Text] [Related]
16. PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis.
Ray ME; Thames HD; Levy LB; Horwitz EM; Kupelian PA; Martinez AA; Michalski JM; Pisansky TM; Shipley WU; Zelefsky MJ; Zietman AL; Kuban DA
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1140-50. PubMed ID: 16198506
[TBL] [Abstract][Full Text] [Related]
17. Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland.
Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):664-73. PubMed ID: 11849788
[TBL] [Abstract][Full Text] [Related]
18. Importance of high radiation doses (72 Gy or greater) in the treatment of stage T1-T3 adenocarcinoma of the prostate.
Lyons JA; Kupelian PA; Mohan DS; Reddy CA; Klein EA
Urology; 2000 Jan; 55(1):85-90. PubMed ID: 10654900
[TBL] [Abstract][Full Text] [Related]
19. Conventional external-beam radiation therapy alone or with androgen ablation for clinical stage III (T3, NX/N0, M0) adenocarcinoma of the prostate.
Zagars GK; Pollack A; Smith LG
Int J Radiat Oncol Biol Phys; 1999 Jul; 44(4):809-19. PubMed ID: 10386637
[TBL] [Abstract][Full Text] [Related]
20. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer.
Zelefsky MJ; Fuks Z; Hunt M; Lee HJ; Lombardi D; Ling CC; Reuter VE; Venkatraman ES; Leibel SA
J Urol; 2001 Sep; 166(3):876-81. PubMed ID: 11490237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]